NDASUSPENSIONINJECTABLE
Approved
Nov 2007
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
15
Data completeness
4/8 — Partial
TRIESENCE (triamcinolone acetonide) by Alcon is corticosteroid hormone receptor agonists [moa]. Approved for diabetic macular edema, acute gout, uveitis and 1 more indications. First approved in 2007.
Drug data last refreshed 18h ago
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Indications (4)
Worked on TRIESENCE at Alcon? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.